Skip to main content
Top

03-02-2025 | Practical Application

Qualitative In-trial Interviews: Methods, Challenges, and Best Practice

Authors: Nicola Williamson, Chloe Howse, Nicola Hodson, Julia Stein, Rob Arbuckle

Published in: The Patient - Patient-Centered Outcomes Research

Login to get access

Abstract

Qualitative in-trial interviews with clinical trial participants are a means of providing rich, in-depth patient experience data to supplement and complement data captured by clinical outcome assessments and other clinical trial efficacy endpoints. Such in-trial interview data can be used to build understanding of disease and treatment experiences, evaluate content validity of clinical outcome assessments, aid interpretation of scores and meaningful changes, inform trial design feasibility and operational considerations, and provide supportive evidence regarding safety, efficacy, and effectiveness. Despite the rapid growth of in-trial interviews as part of clinical development programs in the pharmaceutical industry in recent years, published guidelines regarding the methods, conduct, and implementation of in-trial interviews are scarce. Drawing on published examples and the authors’ experiences of conducting in-trial interview studies, this article provides an overview of best practice methods for implementing this methodology (including considerations for study design, sample size, interview conduct, and analysis) and the value of in-trial interview data to answer specific research questions. Operational and logistical considerations are outlined, including recommendations for country selection, site selection, training and communication, adverse event safety reporting, and data management and handling. Well-designed and carefully implemented in-trial interviews can lead to generation of insightful patient experience data that are truly of value to inform regulators, health technology agencies, clinicians, patients, and caregivers about product attributes and the impact of diseases and treatments on patients’ lives.
Literature
1.
go back to reference Williamson N, Wells J. Qualitative interviews to elicit patient experience data in clinical studies, oral presentation as part of Session 3: Qualitative methods in clinical trials opportunities and challenges. Silver Spring, MD: Critical Path Institute 14th Annual Patient-Reported Outcome Consortium Workshop; 2023. Williamson N, Wells J. Qualitative interviews to elicit patient experience data in clinical studies, oral presentation as part of Session 3: Qualitative methods in clinical trials opportunities and challenges. Silver Spring, MD: Critical Path Institute 14th Annual Patient-Reported Outcome Consortium Workshop; 2023.
2.
go back to reference Williamson N, Tabberer M, Vashi P, Gibbons E, Tatlock S. Application and value of qualitative in-trial or exit interviews to generate supplementary evidence regarding patients' trial, treatment, and disease experiences: examples from multiple disease areas. Virtual event: International Society for Quality of Life Research conference; 2020. Williamson N, Tabberer M, Vashi P, Gibbons E, Tatlock S. Application and value of qualitative in-trial or exit interviews to generate supplementary evidence regarding patients' trial, treatment, and disease experiences: examples from multiple disease areas. Virtual event: International Society for Quality of Life Research conference; 2020.
3.
go back to reference Williamson N, Bonner N, Wells J. Qualitative in-trial or exit interview methods to elicit supplementary patient experience data during clinical studies. Prague: International Society for Quality of Life Research conference; 19–22 October 2022. Williamson N, Bonner N, Wells J. Qualitative in-trial or exit interview methods to elicit supplementary patient experience data during clinical studies. Prague: International Society for Quality of Life Research conference; 19–22 October 2022.
4.
go back to reference Williamson N, Howse C, Stein J, Hodson N, Arbuckle R, Wells JR. A structured review of the use of qualitative interviews with clinical trial participants to generate patient experience data for clinical development programs [oral presentation]. Calgary: International Society for Quality of Life Research conference; 2023. Williamson N, Howse C, Stein J, Hodson N, Arbuckle R, Wells JR. A structured review of the use of qualitative interviews with clinical trial participants to generate patient experience data for clinical development programs [oral presentation]. Calgary: International Society for Quality of Life Research conference; 2023.
5.
go back to reference US Food and Drug Administration. Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making: guidance for industry, food and drug administration staff, and other stakeholders. Silver Spring: US FDA; 2023. https://www.fda.gov/media/166830/download US Food and Drug Administration. Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making: guidance for industry, food and drug administration staff, and other stakeholders. Silver Spring: US FDA; 2023. https://​www.​fda.​gov/​media/​166830/​download
6.
go back to reference US Food and Drug Administration. Patient-focused drug development: methods to identify what is important to patients: guidance for industry, food and drug administration staff, and other stakeholders. Silver Spring: US FDA; 2022. US Food and Drug Administration. Patient-focused drug development: methods to identify what is important to patients: guidance for industry, food and drug administration staff, and other stakeholders. Silver Spring: US FDA; 2022.
7.
go back to reference US Food and Drug Administration. Patient-focused drug development: selecting, developing, or modifying fit-forpurpose clinical outcome assessments: guidance for industry, food and drug administration staff, and other stakeholders. Silver Spring: US FDA; 2022. US Food and Drug Administration. Patient-focused drug development: selecting, developing, or modifying fit-forpurpose clinical outcome assessments: guidance for industry, food and drug administration staff, and other stakeholders. Silver Spring: US FDA; 2022.
8.
go back to reference US Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input: guidance for industry, food and drug administration staff, and other stakeholders. Silver Spring: US FDA; 2020. US Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input: guidance for industry, food and drug administration staff, and other stakeholders. Silver Spring: US FDA; 2020.
9.
go back to reference US Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Silver Spring: US FDA; 2009. US Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Silver Spring: US FDA; 2009.
10.
go back to reference Alladin A, Barrio J, Dikariyanto V, Venerus M, Rolst M, Krol M. PCR14 A literature review of methodology used in in-trial interview studies in clinical development. Value Health. 2022;25(12):S392.CrossRef Alladin A, Barrio J, Dikariyanto V, Venerus M, Rolst M, Krol M. PCR14 A literature review of methodology used in in-trial interview studies in clinical development. Value Health. 2022;25(12):S392.CrossRef
11.
12.
go back to reference Hawken N, Falissard B, Choquet C, Francois C, Tardu J, Schmid R. Exit interviews from two randomised placebo-controlled phase 3 studies with caregivers of young children with autism spectrum disorder. Front Child Adolesc Psychiatry. 2024;3:1236340.PubMedPubMedCentralCrossRef Hawken N, Falissard B, Choquet C, Francois C, Tardu J, Schmid R. Exit interviews from two randomised placebo-controlled phase 3 studies with caregivers of young children with autism spectrum disorder. Front Child Adolesc Psychiatry. 2024;3:1236340.PubMedPubMedCentralCrossRef
13.
go back to reference Ervin C, Joish VN, Evans E, DiBenedetti D, Reaney M, Preblick R, Castro R, Danne T, Buse JB, Lapuerta P. Insights into patients’ experience with type 1 diabetes: exit interviews from phase III studies of sotagliflozin. Clin Ther. 2019;41(11):2219–30.PubMedCrossRef Ervin C, Joish VN, Evans E, DiBenedetti D, Reaney M, Preblick R, Castro R, Danne T, Buse JB, Lapuerta P. Insights into patients’ experience with type 1 diabetes: exit interviews from phase III studies of sotagliflozin. Clin Ther. 2019;41(11):2219–30.PubMedCrossRef
15.
go back to reference Evitt L, Follows R, Bentley J, Williams W, Shalhoub H, Celone M, von Maltzahn R. Mepolizumab prefilled autoinjector and prefilled syringe real world use: the patient experience. In: A32. Asthma: Clinical Studies II. American Thoracic Society; 2019; A1307. Evitt L, Follows R, Bentley J, Williams W, Shalhoub H, Celone M, von Maltzahn R. Mepolizumab prefilled autoinjector and prefilled syringe real world use: the patient experience. In: A32. Asthma: Clinical Studies II. American Thoracic Society; 2019; A1307.
18.
go back to reference Weiss C, Meehan SR, Brown TM, Gupta C, Mørup MF, Thase ME, McIntyre RS, Ismail Z. Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews. J Patient Rep Outcomes. 2021;5(1):128.PubMedPubMedCentralCrossRef Weiss C, Meehan SR, Brown TM, Gupta C, Mørup MF, Thase ME, McIntyre RS, Ismail Z. Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews. J Patient Rep Outcomes. 2021;5(1):128.PubMedPubMedCentralCrossRef
20.
go back to reference Ervin C, Joish VN, Castro C, DiBenedetti D, Evans E, Carroll A, Lapuerta P. MON-630 Elevating the patient voice in type 1 diabetes clinical trials: a comparison of in-depth exit interviews and diabetes-specific questionnaires. J Endocr Soc. 2020;4(Suppl 1):MON-630.PubMedCentralCrossRef Ervin C, Joish VN, Castro C, DiBenedetti D, Evans E, Carroll A, Lapuerta P. MON-630 Elevating the patient voice in type 1 diabetes clinical trials: a comparison of in-depth exit interviews and diabetes-specific questionnaires. J Endocr Soc. 2020;4(Suppl 1):MON-630.PubMedCentralCrossRef
21.
go back to reference Mahon-Smith A, Clifford M, Batish A, Sharp R, Panter C, Naujoks C, Schruf E, Compagno N, Moreno SG. Patient experience of lichen planus: a qualitative exploration of signs, symptoms, and health-related quality of life impacts. Dermatol Ther. 2023;13(9):2001–17.CrossRef Mahon-Smith A, Clifford M, Batish A, Sharp R, Panter C, Naujoks C, Schruf E, Compagno N, Moreno SG. Patient experience of lichen planus: a qualitative exploration of signs, symptoms, and health-related quality of life impacts. Dermatol Ther. 2023;13(9):2001–17.CrossRef
22.
go back to reference Jan de Beur SM, Cimms T, Nixon A, Theodore-Oklota C, Luca D, Roberts MS, Egan S, Graham CA, Hribal E, Evans CJ. Burosumab improves patient-reported outcomes in adults with tumor-induced osteomalacia: mixed-methods analysis. J Bone Min Res. 2023;38(11):1654–64.CrossRef Jan de Beur SM, Cimms T, Nixon A, Theodore-Oklota C, Luca D, Roberts MS, Egan S, Graham CA, Hribal E, Evans CJ. Burosumab improves patient-reported outcomes in adults with tumor-induced osteomalacia: mixed-methods analysis. J Bone Min Res. 2023;38(11):1654–64.CrossRef
23.
go back to reference Chan EK, Williams V, Romano C, Fehnel S, Slagle AF, Stoddard J, Sadoff J, Mayorga M, Lewis S, Yarr S. Psychometric evaluation of the Symptoms of Infection with Coronavirus-19 (SIC): results from a cross-sectional study and a phase 3 clinical trial. J Patient Rep Outcomes. 2023;7(1):45.PubMedPubMedCentralCrossRef Chan EK, Williams V, Romano C, Fehnel S, Slagle AF, Stoddard J, Sadoff J, Mayorga M, Lewis S, Yarr S. Psychometric evaluation of the Symptoms of Infection with Coronavirus-19 (SIC): results from a cross-sectional study and a phase 3 clinical trial. J Patient Rep Outcomes. 2023;7(1):45.PubMedPubMedCentralCrossRef
25.
go back to reference Browning JC, Cartwright M, Thorla I Jr, Martin SA, Olayinka-Amao O, Maeda-Chubachi T. A patient-centered perspective of molluscum contagiosum as reported by B-SIMPLE4 clinical trial patients and caregivers: global impression of change and exit interview substudy results. Am J Clin Dermatol. 2023;24(1):119–33.PubMedCrossRef Browning JC, Cartwright M, Thorla I Jr, Martin SA, Olayinka-Amao O, Maeda-Chubachi T. A patient-centered perspective of molluscum contagiosum as reported by B-SIMPLE4 clinical trial patients and caregivers: global impression of change and exit interview substudy results. Am J Clin Dermatol. 2023;24(1):119–33.PubMedCrossRef
26.
go back to reference Hudgens S, Howerter A, Polek E, Andersson FL. Psychometric validation and interpretation of the Nocturia Impact Diary in a clinical trial setting. Qual Life Res. 2022;31(6):1837–48.PubMedCrossRef Hudgens S, Howerter A, Polek E, Andersson FL. Psychometric validation and interpretation of the Nocturia Impact Diary in a clinical trial setting. Qual Life Res. 2022;31(6):1837–48.PubMedCrossRef
27.
go back to reference Simmons A, O’Sullivan AK, Carpenter-Conlin J, Carty MK, Saucier C, McDonnell D. Using qualitative exit interviews to explore schizophrenia burden and treatment experience in clinical trial patients. Front Psychiatry. 2024;15:1377174.PubMedPubMedCentralCrossRef Simmons A, O’Sullivan AK, Carpenter-Conlin J, Carty MK, Saucier C, McDonnell D. Using qualitative exit interviews to explore schizophrenia burden and treatment experience in clinical trial patients. Front Psychiatry. 2024;15:1377174.PubMedPubMedCentralCrossRef
28.
go back to reference Nakamura K, Sakai N, Hossain MA, Eisengart JB, Yamamoto T, Tanizawa K, So S, Schmidt M, Sato Y. Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in Japan. Orphanet J Rare Dis. 2024;19(1):104.PubMedPubMedCentralCrossRef Nakamura K, Sakai N, Hossain MA, Eisengart JB, Yamamoto T, Tanizawa K, So S, Schmidt M, Sato Y. Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in Japan. Orphanet J Rare Dis. 2024;19(1):104.PubMedPubMedCentralCrossRef
30.
go back to reference Cardellino A, Correll JR, Martin M, Gorsh B, Sapra S, Popat R. Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study. Front Oncol. 2023;13:1274659.PubMedPubMedCentralCrossRef Cardellino A, Correll JR, Martin M, Gorsh B, Sapra S, Popat R. Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study. Front Oncol. 2023;13:1274659.PubMedPubMedCentralCrossRef
31.
go back to reference Merker V, Von Imhof L, Park E, Babovic-Vuksanovic D, NghiemPhu P, Yohay K, Plotkin S. CLRM-16 Patient-focused drug development in neuro-oncology: a pilot study of qualitative patient interviews embedded within a neurofibromatosis 2 clinical trial. Neurooncol Adv. 2022;4(Suppl 1):i9–i9.PubMedCentral Merker V, Von Imhof L, Park E, Babovic-Vuksanovic D, NghiemPhu P, Yohay K, Plotkin S. CLRM-16 Patient-focused drug development in neuro-oncology: a pilot study of qualitative patient interviews embedded within a neurofibromatosis 2 clinical trial. Neurooncol Adv. 2022;4(Suppl 1):i9–i9.PubMedCentral
32.
go back to reference Tabberer M, Williamson N, Tatlock S, Gater A, Grimes R, Akinseye C, Neil D, Mahon-Smith A, Nelsen L. Qualitative interviews of patients with COPD and muscle weakness enrolled in a clinical trial evaluating a new anabolic treatment: patient perspectives of disease experience, trial participation and outcome assessments. J Patient Rep Outcomes. 2024;8(1):45. https://doi.org/10.1186/s41687-024-00712-0.CrossRefPubMedPubMedCentral Tabberer M, Williamson N, Tatlock S, Gater A, Grimes R, Akinseye C, Neil D, Mahon-Smith A, Nelsen L. Qualitative interviews of patients with COPD and muscle weakness enrolled in a clinical trial evaluating a new anabolic treatment: patient perspectives of disease experience, trial participation and outcome assessments. J Patient Rep Outcomes. 2024;8(1):45. https://​doi.​org/​10.​1186/​s41687-024-00712-0.CrossRefPubMedPubMedCentral
33.
go back to reference Litcher-Kelly L, Ozen A, Ollis S, Feldman HB, Yaworsky A, Medrano P, Chongsrisawa V, Brackin T, Perlee L, Walker M. Pozelimab for CHAPLE disease: results from in-trial interviews and clinical outcome assessments. Orphanet J Rare Dis. 2024;19(1):290.PubMedPubMedCentralCrossRef Litcher-Kelly L, Ozen A, Ollis S, Feldman HB, Yaworsky A, Medrano P, Chongsrisawa V, Brackin T, Perlee L, Walker M. Pozelimab for CHAPLE disease: results from in-trial interviews and clinical outcome assessments. Orphanet J Rare Dis. 2024;19(1):290.PubMedPubMedCentralCrossRef
34.
go back to reference Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Horsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Oberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB. Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clin Ther. 2017;39(11):2158–68. https://doi.org/10.1016/j.clinthera.2017.09.013.CrossRefPubMed Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Horsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Oberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB. Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clin Ther. 2017;39(11):2158–68. https://​doi.​org/​10.​1016/​j.​clinthera.​2017.​09.​013.CrossRefPubMed
35.
go back to reference Gibble T, Macey J, Makin H, Rosu R, Mellor K, Kitchen H, Carlier H, Dubinsky M. P720 Exit interviews exploring Crohn’s disease patients’ experience of changes in their bowel urgency during the mirikizumab Phase 3 clinical trial in adult patients with moderate to severe Crohn disease. J Crohns Colitis. 2024;18(Suppl 1):i1353–4.CrossRef Gibble T, Macey J, Makin H, Rosu R, Mellor K, Kitchen H, Carlier H, Dubinsky M. P720 Exit interviews exploring Crohn’s disease patients’ experience of changes in their bowel urgency during the mirikizumab Phase 3 clinical trial in adult patients with moderate to severe Crohn disease. J Crohns Colitis. 2024;18(Suppl 1):i1353–4.CrossRef
36.
go back to reference Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2–assessing respondent understanding. Value Health. 2011;14(8):978–88. https://doi.org/10.1016/j.jval.2011.06.013.CrossRefPubMed Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2–assessing respondent understanding. Value Health. 2011;14(8):978–88. https://​doi.​org/​10.​1016/​j.​jval.​2011.​06.​013.CrossRefPubMed
37.
go back to reference Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1–eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–77. https://doi.org/10.1016/j.jval.2011.06.014.CrossRefPubMed Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1–eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–77. https://​doi.​org/​10.​1016/​j.​jval.​2011.​06.​014.CrossRefPubMed
38.
go back to reference Willis GB, Artino AR Jr. What do our respondents think we’re asking? Using cognitive interviewing to improve medical education surveys. J Grad Med Educ. 2013;5(3):353–6.PubMedPubMedCentralCrossRef Willis GB, Artino AR Jr. What do our respondents think we’re asking? Using cognitive interviewing to improve medical education surveys. J Grad Med Educ. 2013;5(3):353–6.PubMedPubMedCentralCrossRef
39.
go back to reference Edgar CJ, Bush EN, Adams HR, Ballinger R, Byrom B, Campbell M, Eremenco S, McDougall F, Papadopoulos E, Slagle AF. Recommendations on the selection, development, and modification of performance outcome assessments: a good practices Report of an ISPOR Task Force. Value Health. 2023;26(7):959–67.PubMedCrossRef Edgar CJ, Bush EN, Adams HR, Ballinger R, Byrom B, Campbell M, Eremenco S, McDougall F, Papadopoulos E, Slagle AF. Recommendations on the selection, development, and modification of performance outcome assessments: a good practices Report of an ISPOR Task Force. Value Health. 2023;26(7):959–67.PubMedCrossRef
40.
go back to reference Dellon ES, Karantzoulis S, Sparling N, Rohay J, Whitsett J, Slagle A, Eagle G, Nezamis J, Knoop K, Paty J. Compliance for the prose daily diary: measuring completion rates of a new instrument to measure dysphagia episodes in patients with eosinophilic esophagitis. United Eur Gastroenterol J. 2021;9:262–907. Dellon ES, Karantzoulis S, Sparling N, Rohay J, Whitsett J, Slagle A, Eagle G, Nezamis J, Knoop K, Paty J. Compliance for the prose daily diary: measuring completion rates of a new instrument to measure dysphagia episodes in patients with eosinophilic esophagitis. United Eur Gastroenterol J. 2021;9:262–907.
42.
go back to reference Ventola P, Jaeger J, Keary CJ, Kolevzon A, Adams M, Keshavan B, Zinger-Salmun C, Ochoa-Lubinoff C. An adapted clinical global Impression of improvement for use in Angelman syndrome: validation analyses utilizing data from the NEPTUNE study. Eur J Paediatr Neurol. 2023;47:35–40.PubMedCrossRef Ventola P, Jaeger J, Keary CJ, Kolevzon A, Adams M, Keshavan B, Zinger-Salmun C, Ochoa-Lubinoff C. An adapted clinical global Impression of improvement for use in Angelman syndrome: validation analyses utilizing data from the NEPTUNE study. Eur J Paediatr Neurol. 2023;47:35–40.PubMedCrossRef
43.
go back to reference Bharmal M, Guillemin I, Marrel A, Arnould B, Lambert J, Hennessy M, Fofana F. How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial. Orphanet J Rare Dis. 2018;13:1–10.CrossRef Bharmal M, Guillemin I, Marrel A, Arnould B, Lambert J, Hennessy M, Fofana F. How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial. Orphanet J Rare Dis. 2018;13:1–10.CrossRef
44.
go back to reference Clinch S, Hudgens S, Gibbons E, Willgoss T, Smith J, Polek E, Burbridge C. Quantitative and qualitative exploration of meaningful change on the Vineland Adaptive Behavior Scales (Vineland™-II) in children and adolescents with autism without intellectual disability following participation in a clinical trial. Patient Relat Outcome Meas. 2023;14:337–54.PubMedPubMedCentralCrossRef Clinch S, Hudgens S, Gibbons E, Willgoss T, Smith J, Polek E, Burbridge C. Quantitative and qualitative exploration of meaningful change on the Vineland Adaptive Behavior Scales (Vineland™-II) in children and adolescents with autism without intellectual disability following participation in a clinical trial. Patient Relat Outcome Meas. 2023;14:337–54.PubMedPubMedCentralCrossRef
46.
go back to reference Schiffmann R, Mengel E, Wallace M, Rochmann C, Turnbull J, Krupnick R, Gwaltney C, Pulikottil-Jacob R, Batsu I, Zheng R. Qualitative study of the patient experience with venglustat for Gaucher disease type 3 in a phase 2 open-label, multicenter, multinational study (LEAP). Adv Ther. 2024;41(7):2907–23.PubMedPubMedCentralCrossRef Schiffmann R, Mengel E, Wallace M, Rochmann C, Turnbull J, Krupnick R, Gwaltney C, Pulikottil-Jacob R, Batsu I, Zheng R. Qualitative study of the patient experience with venglustat for Gaucher disease type 3 in a phase 2 open-label, multicenter, multinational study (LEAP). Adv Ther. 2024;41(7):2907–23.PubMedPubMedCentralCrossRef
47.
go back to reference Glaser B, Strauss A. Discovery of grounded theory: strategies for qualitative research. Routledge; 2017.CrossRef Glaser B, Strauss A. Discovery of grounded theory: strategies for qualitative research. Routledge; 2017.CrossRef
48.
go back to reference Francis JJ, Johnston M, Robertson C, Glidewell L, Entwistle V, Eccles MP, Gimshaw JM. What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health. 2010;25(10):1229–45.PubMedCrossRef Francis JJ, Johnston M, Robertson C, Glidewell L, Entwistle V, Eccles MP, Gimshaw JM. What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health. 2010;25(10):1229–45.PubMedCrossRef
49.
go back to reference Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18(1):59–82.CrossRef Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18(1):59–82.CrossRef
50.
go back to reference Lamoureux R, Shields A, Stokes J, Yan G. How many subjects are enough for symptom-focused concept elicitation studies? A retrospective analysis of saturation across twenty-six studies. Value Health. 2015;18(3):A33.CrossRef Lamoureux R, Shields A, Stokes J, Yan G. How many subjects are enough for symptom-focused concept elicitation studies? A retrospective analysis of saturation across twenty-six studies. Value Health. 2015;18(3):A33.CrossRef
52.
go back to reference Peterson CH, Peterson NA, Powell KG. Cognitive interviewing for item development: validity evidence based on content and response processes. Meas EvalCouns Dev. 2017;50(4):217–23.CrossRef Peterson CH, Peterson NA, Powell KG. Cognitive interviewing for item development: validity evidence based on content and response processes. Meas EvalCouns Dev. 2017;50(4):217–23.CrossRef
53.
go back to reference Alladin A, Barrio J, Dikariyanto V, Venerus M, Rolst M, M. K A literature review of methodology used in in-trial interview studies in clinical development. In: ISPOR Europe, 2022; pp 6–9. Alladin A, Barrio J, Dikariyanto V, Venerus M, Rolst M, M. K A literature review of methodology used in in-trial interview studies in clinical development. In: ISPOR Europe, 2022; pp 6–9.
54.
go back to reference Sturges JE. Hanrahan K J Comparing telephone and face-to-face qualitative interviewing: a research note. Qual Res. 2004;4(1):107–18.CrossRef Sturges JE. Hanrahan K J Comparing telephone and face-to-face qualitative interviewing: a research note. Qual Res. 2004;4(1):107–18.CrossRef
55.
go back to reference Block ES, Erskine L. Interviewing by telephone: specific considerations, opportunities, and challenges. Int J Qual Methods. 2012;4:428–45.CrossRef Block ES, Erskine L. Interviewing by telephone: specific considerations, opportunities, and challenges. Int J Qual Methods. 2012;4:428–45.CrossRef
56.
go back to reference Cachia M, Millward L. The telephone medium and semi-structured interviews: a complementary fit. Qual Res Organ Manage. 2011;6(3):265–77.CrossRef Cachia M, Millward L. The telephone medium and semi-structured interviews: a complementary fit. Qual Res Organ Manage. 2011;6(3):265–77.CrossRef
57.
go back to reference Shapka JD, Domene JF, Khan S, Yang LM. Online versus in-person interviews with adolescents: an exploration of data equivalence. Comput Human Behav. 2016;58:361–7.CrossRef Shapka JD, Domene JF, Khan S, Yang LM. Online versus in-person interviews with adolescents: an exploration of data equivalence. Comput Human Behav. 2016;58:361–7.CrossRef
58.
go back to reference Vogl S. Telephone versus face-to-face interviews: mode effect on semistructured interviews with children. Sociolog Methodol. 2013;43(1):133–77.CrossRef Vogl S. Telephone versus face-to-face interviews: mode effect on semistructured interviews with children. Sociolog Methodol. 2013;43(1):133–77.CrossRef
59.
go back to reference Braun V, Clarke V. Using thematic analysis in psychology. Qual ResPsychol. 2006;3(2):77–101. Braun V, Clarke V. Using thematic analysis in psychology. Qual ResPsychol. 2006;3(2):77–101.
62.
go back to reference Joffe H, Yardley L. Content and thematic analysis. In: Marks D, Yardley L, editors. Research methods for clinical and health psychology. London: Sage Publications; 2004. Joffe H, Yardley L. Content and thematic analysis. In: Marks D, Yardley L, editors. Research methods for clinical and health psychology. London: Sage Publications; 2004.
63.
go back to reference US Food and Drug Administration. Statistical review and evaluation. Silver Spring: US FDA; 2016. US Food and Drug Administration. Statistical review and evaluation. Silver Spring: US FDA; 2016.
65.
go back to reference Canadian Agency for Drugs and Technologies in Health. Guidance for providing patient input. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2020. Canadian Agency for Drugs and Technologies in Health. Guidance for providing patient input. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2020.
69.
go back to reference DiBenedetti D. Clinical trial exit interviews with patients (and caregivers). Presented at the clinical outcome assessments: establishing and interpreting meaningful within-patient change meeting; Washington, DC; 2017. DiBenedetti D. Clinical trial exit interviews with patients (and caregivers). Presented at the clinical outcome assessments: establishing and interpreting meaningful within-patient change meeting; Washington, DC; 2017.
70.
go back to reference Gelhorn HL, Kulke MH, O’Dorisio T, Yang QM, Jackson J, Jackson S, Boehm KA, Law L, Kostelec J, Auguste P. Patient-reported symptom experiences in patients with carcinoid syndrome after participation in a study of telotristat etiprate: a qualitative interview approach. Clin Ther. 2016;38(4):759–68.PubMedPubMedCentralCrossRef Gelhorn HL, Kulke MH, O’Dorisio T, Yang QM, Jackson J, Jackson S, Boehm KA, Law L, Kostelec J, Auguste P. Patient-reported symptom experiences in patients with carcinoid syndrome after participation in a study of telotristat etiprate: a qualitative interview approach. Clin Ther. 2016;38(4):759–68.PubMedPubMedCentralCrossRef
71.
go back to reference US Food and Drug Administration. FDA review of telotristat. Clinical Outcome Assessment Consult Review for Xermelo (NDA application 208794). Silver Spring: US FDA; 2016. US Food and Drug Administration. FDA review of telotristat. Clinical Outcome Assessment Consult Review for Xermelo (NDA application 208794). Silver Spring: US FDA; 2016.
75.
go back to reference Koochaki P, Revicki D, Wilson H, Pokrzywinski R, Jordan R, Lucas J, Williams LA, Sadiq A, Krop J. The patient experience of premenopausal women treated with bremelanotide for hypoactive sexual desire disorder: RECONNECT exit study results. J Womens Health (Larchmt). 2021;30(4):587–95. https://doi.org/10.1089/jwh.2020.8460.CrossRefPubMed Koochaki P, Revicki D, Wilson H, Pokrzywinski R, Jordan R, Lucas J, Williams LA, Sadiq A, Krop J. The patient experience of premenopausal women treated with bremelanotide for hypoactive sexual desire disorder: RECONNECT exit study results. J Womens Health (Larchmt). 2021;30(4):587–95. https://​doi.​org/​10.​1089/​jwh.​2020.​8460.CrossRefPubMed
Metadata
Title
Qualitative In-trial Interviews: Methods, Challenges, and Best Practice
Authors
Nicola Williamson
Chloe Howse
Nicola Hodson
Julia Stein
Rob Arbuckle
Publication date
03-02-2025
Publisher
Springer International Publishing
Published in
The Patient - Patient-Centered Outcomes Research
Print ISSN: 1178-1653
Electronic ISSN: 1178-1661
DOI
https://doi.org/10.1007/s40271-024-00726-2

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more